Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · Rbb

F/m Emerald Life Sciences Innovation ETF (LFSC)

Ticker LFSC · · Holdings as of May 31, 2026

Expense ratio
0.54%$54/yr per $10k
Net assets
$105.1Mall share classes
Holdings
40

Bottom line

Is LFSC a good fund? The bottom line

LFSC is a managed technology sector ETF from Rbb.

It charges 0.54% — about $54 a year on every $10,000 invested, cheaper than 75% of technology sector funds we track.

With $105 million in net assets and 40 holdings, its largest position is Travere Therapeutics Inc (7.7%) and the top 10 make up 54.7% of the portfolio.

What stands out

  • Low cost: cheaper than 75% of technology sector peers

What to watch

  • Concentrated: top 10 holdings are 54.7% of assets

Updated Nov 19, 2026

What LFSC invests in

The investment objective of the F/m Emerald Life Sciences Innovation ETF (the Fund) is to seek long-term capital appreciation.

The Fund is an actively managed exchange-traded fund (ETF) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust (the Sub-Adviser), the Funds investment sub-adviser, under the supervision of the Adviser. The Fund intends to identify and invest in unique growth opportunities within the life sciences universe by following scientific, technological and/or strategic innovation. The Sub-Adviser believes that innovative companies are those developing new products or reinventing/redesigning existing products/services, thereby generating value for their customers, creating a competitive advantage and/or driving business growth. The Sub-Adviser applies this theme of innovation by using its proprietary 10-step research process to identify companies that the Sub-Adviser believes are substantially focused on or are expected to…

From the fund's prospectus (filed Jan 5, 2026).

What LFSC costs

On a $10,000 investment, LFSC's 0.54% expense ratio costs about $54 a year. The prospectus estimates $955 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full LFSC fee table →

LFSC top 10 holdings

#Holding% of fund
1Travere Therapeutics Inc TVTX7.67%
2Cogent Biosciences Inc COGT7.53%
3LivaNova PLC LIVN7.11%
4Spyre Therapeutics Inc SYRE6.41%
5Guardant Health Inc GH5.52%
6Mirum Pharmaceuticals Inc MIRM4.92%
7Corcept Therapeutics Inc CORT4.79%
8United Therapeutics Corp UTHR4.16%
9VeraDermics Inc MANE3.42%
10Savara Inc SVRA3.22%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 54.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to LFSC

More funds like LFSC →

LFSC FAQ

What is the expense ratio of LFSC?
LFSC's expense ratio is 0.54%, which works out to about $54 a year for every $10,000 invested. The prospectus estimates total costs of $955 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is LFSC a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 75% of technology sector peers; concentrated: top 10 holdings are 54.7% of assets. This is general information, not personalized advice.
What does LFSC hold?
LFSC's largest holdings are Travere Therapeutics Inc (7.7%), Cogent Biosciences Inc (7.5%), LivaNova PLC (7.1%), Spyre Therapeutics Inc (6.4%), Guardant Health Inc (5.5%). It holds 40 positions in total as of May 31, 2026 (SEC Form N-PORT).
Who manages LFSC?
LFSC is offered by Rbb through Rbb Fund, Inc..